The Alliance of Clinical Trials in Oncology has selected four manuscripts, out of 41 published during 2025-2026, as its most significant publications of the year. The selected studies highlight important advances in cancer research, spanning meningioma, breast cancer, colorectal cancer, and acute lymphoblastic leukemia (ALL).
Chosen by the Alliance Publications Committee, led by Co-Chairs Apar Ganti, MD, of the University of Nebraska Medical Center, and John Grecula, MD, of The Ohio State University Comprehensive Cancer Center, the publications reflect research with the potential to influence cancer care, improve clinical trial design, and advance our understanding of cancer biology.
Alliance committee chairs and the principal investigators of the Cancer Control Program, Statistics and Data Management Program, and Translational Research Program began the selection process by nominating up to three manuscripts demonstrating the potential to change the standard of care, improve how clinical trials are designed and conducted, or provide important new insights into cancer biology. The process also emphasized the contributions of emerging investigators, with each group asked to include at least one qualifying publication led by a junior investigator, when available.
A separate review panel, composed of select members of Alliance scientific leadership, evaluated the submissions and assigned individual merit scores. The Publications Committee then considered these scores and reviewer comments to determine the final selections.
Together, the four publications showcase the breadth and impact of Alliance research, highlighting discoveries and innovations that have the potential to shape the future of cancer treatment and clinical research. The four selected manuscripts are:
Abemaciclib in Meningiomas with Somatic NF2 or CDK Pathway Alterations: the Phase 2 Alliance A071401 Trial
Nat Med 32, 717–724 (2026)
Priscilla K. Brastianos, Katharine Dooley, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Maria Martinez-Lage, Mohammed Milhem, Mary Roberta Welch, Thomas J. Kaley, Jan Drappatz, Amy Chan, Priya Kumthekar, Carlos Kamiya Matsuoka, Roy E. Strowd, Adam L. Cohen, Kurt Jaeckle, Lindsay Robell, Rajiv S. Magge, Joo Yeon Nam, Nicholas Blondin, Nawal Shaikh, Ian Rabinowitz, Alissa A. Thomas, David E. Piccioni, Paul Brown, Stefan Kaluziak, Elizabeth Codd, Daniel P. Cahill, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis
Study: A071401 | Alliance Funding: U10CA180821, U10CA180882
Synopsis: This Phase 2 clinical trial evaluated abemaciclib, an oral targeted cancer drug that blocks CDK4/6 proteins involved in cell growth and division, in patients with recurrent or progressive grade 2 or 3 meningiomas. The patients were selected because their tumors had specific genetic alterations in the NF2 gene or the CDK signaling pathway, two major molecular drivers of uncontrolled cell growth. The study demonstrated that abemaciclib helped stabilize disease in a substantial proportion of patients, with 58% remaining progression-free at six months, although no significant tumor shrinkage was observed. Results suggest that abemaciclib may offer a promising treatment option, particularly for patients with NF2-altered tumors, warranting further investigation. Read more.
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer
N Engl J Med 2026;394:451-462
Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence A Francis, Filipa Lynce, Jane Lanzillotti, Carter DuFrane, Anna Wall, Carrie Strand, Ian Krop, Ines Vaz-Luis, Debu Tripathy, Sherene Loi, Aleix Prat, Matthew Goetz, Santiago Escrivá-de-Romaní, David Porter, Jennifer Spoenlein, Daniel G Stover, Sagar Sardesai, Pierre Heudel, Maria Koehler, Cynthia Huang Bartlett, Ariadna Holynskyj, Prashanth Gopalakrishna, Eric Gauthier, Suzette Delaloge, Kathy Miller, Eric P Winer, Luca Gianni, Ann H Partridge, Angela DeMichele, Lisa A Carey
Study: AFT-38 PATINA | Alliance Funding: Alliance Foundation Trials
Synopsis: The Phase 3 AFT-38 PATINA trial evaluated the addition of palbociclib, a CDK4/6 inhibitor, to standard maintenance HER2-targeted and endocrine therapy in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer. Among 518 patients, adding palbociclib significantly improved median progression-free survival from 29.1 to 44.3 months, although it increased treatment-related side effects, particularly neutropenia, a condition with low white blood cells that makes it harder for the body to fight infections. These findings support adding palbociclib to maintenance therapy as a strategy to delay disease progression in this patient population. These results led to FDA approval in June 2026 for this maintenance treatment combination, expanding palbociclib’s role in metastatic breast cancer. Read more.
Atezolizumab Plus FOLFOX for Stage III Mismatch Repair Deficient Colon Cancer
N Engl J Med 2026;394:1155-1166
Frank A Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter R Peters, Robert J Behrens, Christopher H Lieu, Khalid Matin, Deirdre J Cohen, Samara L Potter, Andrew B Nixon, Lisa A Kottschade, Emily Kathol, Wendy L Frankel, Ardaman Shergill, Dennis Hsu, Anke Reinacher-Schick, Paul Mehan, Philip J Gold, Maged F Khalil, Tyler Zemla, Clare Gatten, Eileen M O’Reilly, Jeffrey A Meyerhardt
Study: A021502 | Alliance Funding: U10CA180821, U10CA180882
Synopsis: The Phase 3 Alliance A021502 ATOMIC trial evaluated adding atezolizumab, an immunotherapy drug, to standard FOLFOX chemotherapy in patients with stage III mismatch repair-deficient (dMMR) colon cancer that has been surgically removed. Adding atezolizumab significantly improved three-year disease-free survival from 76.2% to 86.3%, reducing the risk of recurrence or death by 50%, although treatment-related adverse events were more frequent. These findings support adding immunotherapy to the standard treatment for stage III dMMR colon cancer, representing a significant advance in reducing recurrence risk. These results led to FDA approval in October 2026, establishing a new immunotherapy option for patients with stage III dMMR colon cancer. Read more.
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults with Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
J Clin Oncol 43, 3526-3535(2025)
Matthew J Wieduwilt, Jun Yin, Oudom Kour, Rebecca Teske, Wendy Stock, Carolin Escherich, Jun Yang, Zhenhua Li, Kenneth Byrd, Kimberley Doucette, James Mangan, Scott Hall, Alice S Mims, Katarzyna Jamieson, Shira N Dinner, Ali W Bseiso, Giorgia Giordano, Caner Saygin, Geoffrey L Uy, Mark R Litzow, Richard M Stone
Study: A041703 | Alliance Funding: U10CA180821, U10CA180882
Synopsis: The Phase 2 Alliance A041703 trial evaluated a chemotherapy-free regimen using two targeted therapies, inotuzumab ozogamicin followed by blinatumomab, in adults aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). The combination achieved a 97% complete remission rate and one-year event-free and overall survival rates of 75% and 85%, respectively. These findings demonstrate promising efficacy in an older population that often cannot tolerate intensive chemotherapy. It also supports this targeted approach as a potential treatment standard, although the study was relatively small (33 patients). The study supports a potentially important shift toward targeted, chemotherapy-sparing treatment for older adults with B-ALL, offering high remission rates and encouraging survival outcomes in a population with historically poor outcomes and limited ability to tolerate intense chemotherapy. Read more.
HONORABLE MENTION
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
J Thorac Oncol 2026;21:103650
Allison Booth, Shauna Hillman, Kristina Laumann, Ying-Qi Zhao, Michael LeBlanc, Kari Chansky, Sharmila Giri, Jennifer Dill, Judy Johnson, Kathryn Kelley, Linda Martin, Raymond U Osarogiagbon, Michael J Morris, Anne C Chiang, David E Kozono, Charles D Blanke, Evanthia Galanis, Jhanelle E Gray, Thomas E Stinchcombe, Raid Aljumaily, Daniel Morgensztern, Sumithra J Mandrekar
Study: A082304 | Alliance Funding: U10CA180821, U10CA180882
Synopsis: The PROSPECT-LUNG study introduced a Phase 3 clinical trial model comparing perioperative versus adjuvant immunotherapy-based treatment strategies in patients with resectable non-small cell lung cancer (NSCLC). The study streamlined trial design by reducing protocol length by 65%, patient data collection requirements by 83%, and estimated clinical site workload from 210 to 36.5 hours per patient. This approach demonstrated that cancer clinical trials can be made more efficient, accessible, and less burdensome for patients and research teams while maintaining scientific rigor, potentially accelerating clinical research and improving participation and enrollment in future oncology trials.
Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials
JCO Oncol Pract 0, OP-25-01376
Kever A Lewis, Brian A Colgrove, Garth D Nelson, Qian Shi, Gretchen C Edwards, Matthew H G Katz, George J Chang, Electra D Paskett, Jeffrey A Meyerhardt, Eileen M O’Reilly, Rebecca A Snyder
Studies: Meta Analysis | Alliance Funding: Alliance for Clinical Trials in Oncology Foundation
Synopsis: This study examined the collection and reporting of social determinants of health (SDOH) data across 11 Alliance gastrointestinal cancer clinical trials involving 12,701 patients. Although demographic information, insurance status, and ZIP code were routinely collected, important factors such as education, employment, and marital status were inconsistently captured, and fewer than 2% of related publications reported or analyzed SDOH data. The findings highlight a major gap in cancer clinical research, demonstrating the need for more comprehensive collection and analysis of socioeconomic and social factors to better understand disparities in clinical trial participation, treatment access, and cancer outcomes. Improving SDOH data collection may help make future clinical trials more representative and equitable.
